PL2279200T3 - Biologicznie czynne peptydy - Google Patents

Biologicznie czynne peptydy

Info

Publication number
PL2279200T3
PL2279200T3 PL09743243T PL09743243T PL2279200T3 PL 2279200 T3 PL2279200 T3 PL 2279200T3 PL 09743243 T PL09743243 T PL 09743243T PL 09743243 T PL09743243 T PL 09743243T PL 2279200 T3 PL2279200 T3 PL 2279200T3
Authority
PL
Poland
Prior art keywords
biologically active
active peptides
peptides
biologically
active
Prior art date
Application number
PL09743243T
Other languages
English (en)
Polish (pl)
Inventor
Friedrich Scheiflinger
Michael Dockal
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of PL2279200T3 publication Critical patent/PL2279200T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL09743243T 2008-04-17 2009-04-16 Biologicznie czynne peptydy PL2279200T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10
EP09743243.9A EP2279200B1 (en) 2008-04-17 2009-04-16 Biologically active peptides

Publications (1)

Publication Number Publication Date
PL2279200T3 true PL2279200T3 (pl) 2017-08-31

Family

ID=40887122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09743243T PL2279200T3 (pl) 2008-04-17 2009-04-16 Biologicznie czynne peptydy

Country Status (19)

Country Link
US (6) US8563688B2 (OSRAM)
EP (2) EP3115370B1 (OSRAM)
JP (3) JP6038452B2 (OSRAM)
KR (2) KR101606248B1 (OSRAM)
CN (2) CN105524163A (OSRAM)
AR (1) AR071478A1 (OSRAM)
AU (1) AU2009244635B2 (OSRAM)
BR (1) BRPI0911203A2 (OSRAM)
CA (1) CA2721694C (OSRAM)
DK (2) DK2279200T3 (OSRAM)
ES (2) ES2594706T3 (OSRAM)
HK (1) HK1223946A1 (OSRAM)
MX (1) MX2010011397A (OSRAM)
NZ (1) NZ588200A (OSRAM)
PL (1) PL2279200T3 (OSRAM)
PT (1) PT2279200T (OSRAM)
SG (2) SG10201809286XA (OSRAM)
TW (2) TWI573806B (OSRAM)
WO (1) WO2009137256A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI573806B (zh) * 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
CN103262532B (zh) 2010-07-19 2018-03-09 杜比实验室特许公司 用于经采样复用的图像和视频数据的增强方法
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
EA201491388A1 (ru) 2012-02-15 2015-01-30 Байоджен Айдек Ма Инк. Рекомбинантные белки фактора viii
DK3564260T5 (da) 2012-02-15 2024-09-02 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
BR112015028502B1 (pt) * 2013-06-11 2022-03-22 Cj Cheiljedang Corporation Microrganismo produtor de l-isoleucina e método para a produção de l-isoleucina utilizando o mesmo
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 AvanStrate株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
EP3519431A1 (en) 2016-09-28 2019-08-07 Cohbar Inc. Therapeutic mots-c related peptides
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
CN110831613A (zh) 2017-01-31 2020-02-21 比奥维拉迪维治疗股份有限公司 因子ix融合蛋白及其制备和使用方法
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
EP0805864A1 (en) * 1994-12-30 1997-11-12 Seminis Vegetable Seeds, Inc. Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
IL147269A0 (en) 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
WO2001039799A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Passive desensitization
US20020197266A1 (en) * 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
JP4603240B2 (ja) * 2001-05-11 2010-12-22 リサーチ ディベロップメント ファンデーション NF−κB活性化受容体のインヒビターおよびその使用
FR2830865B1 (fr) * 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
WO2007077560A2 (en) 2006-01-04 2007-07-12 Do-Coop Technologies Ltd. Cryoprotective compositions and methods of using same
TWI573806B (zh) * 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽

Also Published As

Publication number Publication date
NZ588200A (en) 2012-11-30
US20190225648A1 (en) 2019-07-25
AU2009244635B2 (en) 2012-04-19
US9598464B2 (en) 2017-03-21
ES2594706T3 (es) 2016-12-22
US20100022445A1 (en) 2010-01-28
CA2721694A1 (en) 2009-11-12
JP2014074052A (ja) 2014-04-24
US20120077749A1 (en) 2012-03-29
US8563688B2 (en) 2013-10-22
EP3115370A1 (en) 2017-01-11
EP2279200B1 (en) 2016-07-13
HK1154255A1 (zh) 2012-04-13
PT2279200T (pt) 2016-10-12
CN105524163A (zh) 2016-04-27
CN102007140A (zh) 2011-04-06
AU2009244635A1 (en) 2009-11-12
KR20110005873A (ko) 2011-01-19
CN102007140B (zh) 2016-02-24
TW201443085A (zh) 2014-11-16
HK1223946A1 (zh) 2017-08-11
EP2279200A1 (en) 2011-02-02
KR20130112959A (ko) 2013-10-14
US8822638B2 (en) 2014-09-02
JP5977223B2 (ja) 2016-08-24
ES2739676T3 (es) 2020-02-03
AR071478A1 (es) 2010-06-23
TWI573806B (zh) 2017-03-11
JP2017019797A (ja) 2017-01-26
TW200944226A (en) 2009-11-01
US10822376B2 (en) 2020-11-03
WO2009137256A1 (en) 2009-11-12
SG10201608071YA (en) 2016-11-29
US9206234B2 (en) 2015-12-08
US20160060295A1 (en) 2016-03-03
CA2721694C (en) 2018-11-06
EP3115370B1 (en) 2019-06-26
MX2010011397A (es) 2010-11-12
US20170174724A1 (en) 2017-06-22
DK2279200T3 (en) 2016-08-22
KR101606248B1 (ko) 2016-03-24
US20150038676A1 (en) 2015-02-05
JP2011518179A (ja) 2011-06-23
JP6038452B2 (ja) 2016-12-07
US10287319B2 (en) 2019-05-14
SG10201809286XA (en) 2018-11-29
KR101434712B1 (ko) 2014-10-01
TWI541020B (zh) 2016-07-11
BRPI0911203A2 (pt) 2016-07-05
DK3115370T3 (da) 2019-07-29

Similar Documents

Publication Publication Date Title
SG10201608071YA (en) Biologically active peptides
GB0723712D0 (en) Peptides
GB0920981D0 (en) Peptides
GB2462761B (en) Protein formulation
GB0921995D0 (en) Antimicrobial peptides
PL2207790T3 (pl) Biologicznie aktywne peptydy zawierające C-końcową argininę
IL199771A0 (en) Active substance combination
EP2123666A4 (en) PEPTIDE
GB0816976D0 (en) Protein
EP2254901A4 (en) THERAPEUTIC PEPTIDES
GB0703945D0 (en) Peptide
EP2188305A4 (en) MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS
GB0920987D0 (en) Peptides
IL197675A0 (en) Peptides
GB0817978D0 (en) Peptides
GB0818627D0 (en) Protein
GB0812586D0 (en) Chimaeric peptide
GB0815673D0 (en) Peptides
GB0810449D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides
GB0814342D0 (en) Functionalised biologically active surfaces
PL384436A1 (pl) Wibroizolator aktywny
GB0707626D0 (en) Peptides
GB0705115D0 (en) Peptides
GB0705251D0 (en) Peptides